BioViva is a biotechnology company focused on developing gene therapies aimed at the biological mechanisms underlying aging and age-associated disease. Rather than concentrating solely on treating the symptoms that emerge as people grow older, the company’s research centers on cellular processes associated with aging, including telomere attrition, muscle loss, cellular senescence, and mitochondrial dysfunction. Its stated goal is to develop regenerative therapies that address these mechanisms at the cellular level.
One of BioViva’s most distinctive areas of work has been the development of gene-therapy approaches involving telomerase and muscle preservation. Its pipeline includes telomerase-based programs directed toward conditions including Alzheimer’s disease and skin aging, as well as myostatin inhibition for sarcopenia and related disorders. These programs reflect BioViva’s broader strategy of targeting specific biological mechanisms rather than approaching every age-associated disease as an entirely separate problem.
BioViva has also worked on gene-delivery technology. The company describes its CMV platform as a next-generation delivery system designed to address some of the payload limitations associated with smaller viral vectors. Its research program also includes AAV-based therapies, reflecting work across multiple approaches to delivering therapeutic genetic material into cells. Delivery technology is a critical part of gene therapy because the effectiveness of a genetic medicine depends not only on the gene being delivered, but also on whether it can reach the appropriate cells in a controlled manner.
